News for Biomea Fusion Inc Stock (BMEA)

Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze

InvestorPlace • 06/07/24

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm

GlobeNewsWire • 06/07/24

Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

GlobeNewsWire • 06/06/24

Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations

InvestorPlace • 06/06/24

Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

GlobeNewsWire • 05/30/24

Looking for the next meme stock? These stocks are short-squeeze targets

Finbold • 05/14/24

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire • 05/01/24

Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219

GlobeNewsWire • 04/01/24

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

GlobeNewsWire • 04/01/24

7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode

InvestorPlace • 03/07/24

Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

GlobeNewsWire • 03/06/24

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire • 03/01/24

3 Speculative Stocks That Could Make Your February Unforgettable

InvestorPlace • 02/18/24

Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire • 01/09/24

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219

GlobeNewsWire • 01/08/24

Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire • 01/02/24

Short Sellers Think These Stocks Will Tank in 2024. Investors Can Bet Otherwise.

Barrons • 12/29/23

Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why

Zacks Investment Research • 12/12/23

Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH

GlobeNewsWire • 12/11/23

Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts

GlobeNewsWire • 12/09/23

Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resist

GlobeNewsWire • 12/08/23

Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Dis

GlobeNewsWire • 12/07/23

Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

GlobeNewsWire • 12/05/23

Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024

GlobeNewsWire • 11/27/23

Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease

GlobeNewsWire • 11/16/23